Skip to main content
Download PDF

Prostaglandin E1 for preventing the progress of pulmonary arterial hypertension in rat model

Artery Research volume 22, pages 49–56 (2018)Cite this article

Abstract

Pulmonary artery hypertension (PAH) is a progressive chronic disease with a high mortality rate. Increased pulmonary vascular resistance and over-proliferation of pulmonary artery endothelial cells lead to remodeling of pulmonary vasculature. Several anti-PAH therapies targeting various pathways involved in PAH progression have been approved by the FDA. However, many of the currently available anti-PAH drugs suffer from a number of limitations, including short biological half-life, and poor pulmonary selectivity. Prostaglandin E1 (PGE1) is a compound with vasodilatory, anti-inflammatory, anti-aggregatory, and anti-proliferative properties. Recently, PGE1 is known to accumulate in sites of inflammation or vascular lesions and thus enhance the effects of the drugs and alleviate the side effects. Therefore, we hypothesized that long-term effect of PGE1 could reduce ma adaptive structural remodeling of the lung and heart and prevent ventricular arrhythmias in monocrotaline (MCT)-induced rat model of PAH. Our results revealed that PGE1 reduced ventricular hypertrophy, protein expressions of endothelin-1 (ET-1) and endothelin receptor A (ERA), and the expression of fibrosis. These results support the notion that PGE1 can improve the functional properties of RV, highlighting its potential benefits for heart and lung impairment.

References

  1. Liles JT, Hoyer K, Oliver J, Chi L, Dhalla AK, Belardinelli L. Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension. J Pharmacol Exp Ther 2015;353:480–9.

    Google Scholar 

  2. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013–32.

    Google Scholar 

  3. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486–95.

    Google Scholar 

  4. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol 2015;12:143–55.

    Google Scholar 

  5. Voelkel NF, Bogaard HJ, Gomez-Arroyo J. The need to recognize the pulmonary circulation and the right ventricle as an integrated functional unit: facts and hypotheses. Pulm Circ 2015;5:81–9.

    Google Scholar 

  6. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007;29:2134–53.

    Google Scholar 

  7. Galie N, Palazzini M, Leci E, Manes A. Current therapeutic approaches to pulmonary arterial hypertension. Rev Esp Cardiol 2010;63:708–24.

    Google Scholar 

  8. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20–5.

    Google Scholar 

  9. He B, Zhang F, Li X, Lin G, Du J, Jin H. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 2010;74:1458–64.

    Google Scholar 

  10. Fernandes SM, Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau K, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003;91:632–5.

    Google Scholar 

  11. Kloeze J. Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochim Biophys Acta 1969;187:285–92.

    Google Scholar 

  12. Sood BG, Delaney-Black V, Aranda JV, Shankaran S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial. Pediatr Res 2004;56:579–85.

    Google Scholar 

  13. Wallace JL. Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin N Am 1992;21:631–41.

    Google Scholar 

  14. Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998;86:753–8.

    Google Scholar 

  15. Bito LZ, Baroody RA. Comparison of renal prostaglandin and p-aminohippuric acid transport processes. Am J Physiol 1978; 234:F80–8.

  16. Irish III JM. Secretion of prostaglandin E2 by rabbit proximal tubules. Am J Physiol 1979;237:F268–73.

    Google Scholar 

  17. Shen J, He B, Wang B. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. Chest 2005;128:714–9.

    Google Scholar 

  18. Gaskill HV. Intraportal prostaglandin E1 ameliorates the toxicity of intraportal 2′-deoxy-5-fluorouridine in rats. J Surg Res 1987;43:128–32.

    Google Scholar 

  19. Kahky MP, Lind DS, Cruz Jr AB, Gaskill 3rd HV. Prostaglandin E1 enhances tumoricidal activity of 5-fluoro-2′-deoxyuridine in rats. J Surg Res 1991;51:119–23.

    Google Scholar 

  20. Lee JC, Kim KC, Choe SY, Hong YM. Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment. Anat Cell Biol 2016;49:7–14.

    Google Scholar 

  21. Serra W, Musiari L, Ardissino D, Gherli T, Montanari A. Benefit of prostaglandin infusion in severe heart failure Preliminary clinical experience of repetitive administration. Int J Cardiol 2011;146:e10–5.

    Google Scholar 

  22. Metsa-Ketela T. Cyclic AMP-dependent and independent effect of prostaglandins on contraction-relaxation of spontaneously beating isolated rat atria. Acta Physiol Scand 1981;112:481–5.

    Google Scholar 

  23. Shecther MM, Agranat O, Har-Zahav Y, Rath S, Kaplinsky E, Rabinowitz B. Prostaglandin E1 during angioplasty as preventative therapy for coronary restenosis. Am J Ther 1997;4:395–400.

    Google Scholar 

  24. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504–9.

    Google Scholar 

  25. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464–9.

    Google Scholar 

  26. Hiramoto Y, Shioyama W, Kuroda T, Masaki M, Sugiyama S, Okamoto K, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J 2007;71:367–9.

    Google Scholar 

  27. Ma ZS, Ma SJ, Dong MF, Wang JT, Wang LX. Effect of captopril on elevated pulmonary pressure following corrective surgery for tetralogy of Fallot. J Card Surg 2009;24:553–7.

    Google Scholar 

  28. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardio Thorac Surg 2005;28:882–8.

    Google Scholar 

  29. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT). Eur Heart J 2009;30:2493–537.

    Google Scholar 

  30. D'Ambra MN, LaRaia PJ, Philbin DM, Watkins WD, Hilgenberg AD, Buckley MJ. Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 1985; 89:567–72.

    Google Scholar 

  31. Kermode J, Butt W, Shann F. Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J 1991;66:175–8.

    Google Scholar 

  32. Rubis LJ, Stephenson LW, Johnston MR, Nagaraj S, Edmunds Jr LH. Comparison of effects of prostaglandin E1 and nitroprusside on pulmonary vascular resistance in children after open-heart surgery. Ann Thorac Surg 1981;32:563–70.

    Google Scholar 

  33. Kato S, Sugimura H, Kishiro I, Machida M, Suzuki H, Kaneko N. Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with mono-crotaline induced pulmonary hypertension. Exp Lung Res 2002; 28:265–73.

    Google Scholar 

  34. Krieg P, Wahlers T, Giess W, Rohde R, Hartrumpf M, Bund M, et al. Inhaled nitric oxide and inhaled prostaglandin E1: effect on left ventricular contractility when used for treatment of experimental pulmonary hypertension. Eur J Cardio Thorac Surg 1998;14:494–502.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-Gil, 463707, Bundang-Gu, Seongnam-si, Gyeonggi-do, Republic of Korea

    Jae Chul Lee & Chan Yeong Heo

  2. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

    Jae Chul Lee

  3. Department of Biology, School of Life Sciences, Chungbuk National University, 361-763, Cheongju, Republic of Korea

    Soo Young Choe

  4. Department of Nursing, Suwon Women’s University, Onjung-ro 72, 16632, Suwon, Gweonseon-gu, Suwon-si, Gyeonggi-do, Republic of Korea

    Sun Ju Jeong

Authors
  1. Jae Chul Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soo Young Choe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chan Yeong Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sun Ju Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jae Chul Lee or Sun Ju Jeong.

Rights and permissions

This is an open access article distributed under the CC BY-NC license. https://doi.org/creativecommons.org/licenses/by/4.0/

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, J.C., Choe, S.Y., Heo, C.Y. et al. Prostaglandin E1 for preventing the progress of pulmonary arterial hypertension in rat model. Artery Res 22, 49–56 (2018). https://doi.org/10.1016/j.artres.2018.05.001

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.artres.2018.05.001

Keywords

Artery Research

ISSN: 1876-4401

Contact us